Circio Holding ASA (CRNA) 4

[Martins]

Hehe, var mang en båt som sank på vei til og i havfisket, rip never forget. De som ble med opp igjen fikk med seg deres skatter. Jeg selv har tjent greit på Targo/Circio på vei ned med mye flaks, men er ikke en av de som ble med på havfisket så veldig lenge.

[WernerVonHaussenberg]

@Bob_le_Plast

En vinterstorm kan gni sjarken til fyringsved i fjæra, men alt slikt er glemt når man sitter der i juli med midnattsol, tropenetter, ferske lyngenreker og perfekt temperert Chablis

Nu ventes de bærre på at eit internasjenalt trålrederi ser atte konsesjon som dein kravellbygde småsjarken Rundnesbuen Sr. fekk tildelt av departemange på Sirkelær Krabbevaksinasjon kainn ha betydeli økenomisk værdi, og ærværve heile båten med kvota og mainnskap før eit milliardbeløp.

[TekBot]

Circio Holding ASA Final results of the oversubscribed rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 30 January 2026: Reference is made to the stock exchange announcements
published by Circio Holding ASA (the “Company”) on 8 December 2025 regarding
rights issue of up to NOK 50 million in the Company (the “Rights Issue”) and
the preliminary results of the Rights Issue as announced on 29 January 2026.

The subscription period for the Rights Issue expired on 29 January 2026 at
16:30 CET.

The final allocation of the Offer Shares in the Rights Issue has now been
completed by the Company’s board of directors in accordance with the
allocation criteria stated in the resolution made by the general meeting on 12
January 2026 (the “EGM”) and as set out in the Company’s securities note dated
13 January 2026 (the “Securities Note”, and together with a registration
document dated 1 October 2025, a registration document supplement and summary
dated 13 January 2026 comprise the “Prospectus”). The Prospectus is available
on the Company’s website: https://www.circio.com/en/rightsissue2026/.

Circio received subscriptions for NOK 77.9 million in the Rights Issue, which
represents an oversubscription of 56%. Accordingly, the Company will issue
50,000,000 Offer Shares and receive gross proceeds of NOK 50,000,000 from the
Rights Issue. In addition, subscribers in the Rights Issue will, without
additional consideration, receive one warrant (the “Warrants”) for every Offer
Share allocated and paid by them.

As the Rights Issue was oversubscribed, the Company’s share capital will be
increased by NOK 8,995,675.20 through the issuance of 14,992,792 new shares,
at the same subscription price as in the Rights Issue (NOK 1.00 per share), to
the pre-subscribers in the Rights Issue not being allocated Offer Shares and
Warrants for their full pre-subscription amount in the Rights Issue (the
“Private Placement”), in accordance with the resolution made at the EGM. In
addition, subscribers in the Private Placement will, without additional
consideration, receive one warrant for every new share subscribed for in the
Private Placement. The new shares and warrants in the Private Placement will
be issued and delivered at the same time as the Offer Shares and Warrants in
the Rights Issue.

The Company thereby raises a total gross proceeds of NOK 64,992,792.00 from
the Rights Issue and the Private Placement combined, through the issuance of
64,992,792.00 new shares in the Company.

In addition, a total of 2,662,000 new shares (the “Commission Shares”) will be
issued as commission to the pre-subscribers in the Rights Issue, at the same
subscription price as in the Rights Issue. Further, one warrant will be
granted to the pre-subscribers without additional consideration for each
Commission Share issued. The Commission Shares will be issued and delivered at
the same time as the Offer Shares and Warrants in the Rights Issue.

Notifications of allocated Offer Shares and the corresponding subscription
amount to be paid by each subscriber are expected to be available today, on 30
January 2026. Payment for the allocated Offer Shares falls due on 3 February
2026 in accordance with the payment procedures as described in the Prospectus.

The Offer Shares, the new shares issued in the Private Placement and the
Commission Shares may not be transferred or traded before they have been fully
paid and the share capital increases has been registered with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret). Subject to timely
payment of the aggregate subscription amount in the Rights Issue, it is
expected that the share capital increase relating to the Rights Issue will be
registered in the Norwegian Register of Business Enterprises on or about 9
January 2026 and that the Offer Shares will be delivered to the VPS accounts
of the subscribers to whom they are allocated on or about the next business
day.

The Offer Shares are expected to be tradable on Euronext Oslo Børs from and
including 10 February 2026.

Vator Securities AB is acting as manager in the Rights Issue and
Advokatfirmaet Thommessen AS is acting as legal counsel to the Company in
connection with the Rights Issue.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities
Trading Act. The information was submitted for publication at 2026-01-30 14:11
CET.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

– IMPORTANT INFORMATION –
This announcement is not and does not constitute an offer of securities for
sale or a solicitation of an offer to purchase securities of the Company in
the United States or any other jurisdiction. Copies of this document may not
be sent to jurisdictions, or distributed in or sent from jurisdictions, in
which this is barred or prohibited by law. The securities of the Company may
not be offered or sold in the United States absent registration or an
exemption from registration under the U.S. Securities Act of 1933, as amended
(the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act.
No public offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made
by means of a prospectus (the “Prospectus”) which will be prepared and which
is subject to the approval by the Norwegian Financial Supervisory Authority.
This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus will, following publication, be
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Managers.

In any EEA Member State other than Norway, this communication is only
addressed to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Regulation, i.e., only to investors who
can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of, the
Company. Neither the Manager nor any of its affiliates makes any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

Kilde

[Macken_123]

Ikke lett å få ut en børsmelding uten feil, og det gjelder i dag også.
Aksjekapital er forventet registrert i foretaksregisteret 9 januar…

[Investor]

Noen med zero som har fått vite overtegning?

[Xon]

Har du ikke mottatt e-post fra VPUtsteder ?

[tverilytt]

Nordnet kommer vel med egen melding…

[Xon]

Det vises til din tegning i fortrinnsrettsemisjonen i Circio Holding ASA.

Tildelingen i emisjonen er nå klar. For å se antall aksjer du har blitt tildelt, logg inn i VPS Investortjenester. Velg «Hendelser» og så «Tildelinger».

[tverilytt]

Jada, har fått en slik, men det gjaldt tegning hos VPS, har ikke hørt noe om tegning på Zerok-konto.

Fra Nordnet sin informasjon for Zero:

• 29.01.2026 trekker vi penger og tildeler betalte tegnede aksjer (TEGNING). De endres til ordinære aksjer normalt etter rundt 2-4 uker.

  Dette har de trukket fra min Zero konto, for alle TR.

• For hver (1) tegnede aksjer mottas også (1) tegningsopsjoner. Fullstendige vilkår for disse tegningsopsjonene fremgår i prospektet.

• Tegner du aksjer uten tegningsretter vises søknaden på kontoen din som ubetalte tegnede aksjer (SØKNAD). Når vi får beskjed om en eventuell tildeling trekker vi pengene og tildeler aksjer. Det tar normalt 1-2 uker.

  Overtegning stod som SØKNAD, så vi må bare vente da, 1-2 uker…!

[TekBot]

Circio Holding ASA Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 30 January 2026: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the “Company”) earlier today, 30 January
2026, regarding the final results of the rights issue and the private
placement.

The following primary insiders and close associates to primary insiders have
been allocated new shares and warrants in the Rights Issue and Private
Placement, including new shares and warrants as commission for their
pre-subscriptions in the Rights Issue:

• Erik Digman Wiklund, the CEO of the Company, has been allocated 150,000 new
  shares and the corresponding number of warrants in the Rights Issue and
  private placement. In addition, Erik Digman Wiklund has been granted 44,000
  new shares and the corresponding number of warrants as commission for his
  pre-subscription in the Rights Issue.

• Digman AS, a company closely associated with Erik Digman Wiklund, the CEO of
  the Company, has been allocated 250,000 new shares and the corresponding
  number of warrants in the Rights Issue and private placement.

• Ola Melin, Chief Operating Officer of the Company, has been allocated
  150,000 new shares and the corresponding number of warrants in the Rights
  Issue and private placement. In addition, Ola Melin has been granted 16,500
  new shares and the corresponding number of warrants as commission for his
  pre-subscription in the Rights Issue.

• Thomas Birkballe Hansen, Chief Technology Officer of the Company, has been
  allocated 200,000 new shares and the corresponding number of warrants in the
  Rights Issue and private placement. In addition, Thomas Birkballe Hansen has
  been granted 22,000 new shares and the corresponding number of warrants as
  commission for his pre-subscription in the Rights Issue.

• BioPharma Drug Licensing Group SL (“BioPharma”), a company closely
  associated with Lubor Gaal, the CFO of the Company, has been allocated
  270,000 new shares and the corresponding number of warrants in the Rights
  Issue and private placement. In addition, Biopharma has been granted 29,700
  new shares and the corresponding number of warrants as commission for
  pre-subscription in the Rights Issue.

• Victor Levitsky, Chief Scientific Officer of the Company, has been allocated
  250,000 new shares and the corresponding number of warrants in the Rights
  Issue and private placement. In addition, Victor Levitsky has been granted
  27,500 new shares and the corresponding number of warrants as commission for
  his pre-subscription in the Rights Issue.

• Sølen AS, a close associate of Thomas Falck, board member of the board of
  directors of the Company, has been allocated 200,000 new shares, and the
  corresponding number of warrants in the Rights Issue and private placement.
  In addition, Sølen AS has been granted 22,000 new shares and the
  corresponding number of warrants as commission for pre-subscription in the
  Rights Issue.

• Diane Mary Mellett, board member of the board of directors of the Company,
  has been allocated 60,000 new shares and the corresponding number of
  warrants in the Rights Issue and private placement. In addition, Diane Mary
  Mellet has been granted 6,600 new shares and the corresponding number of
  warrants as commission for her pre-subscription in the Rights Issue.

• Robert Forbes Burns, deputy member of the board of directors of the Company,
  has been allocated 11,542 new shares and the corresponding number of
  warrants in the Rights Issue and private placement.

• Damian Marron, the Chairman of the board of directors of the Company, has
  been allocated 120,000 new shares and the corresponding number of warrants
  in the Rights Issue and private placement. In addition, Damian Marron has
  been granted 13,200 new shares and the corresponding number of warrants as
  commission for his pre-subscription in the Rights Issue.

Please see the attached notifications of trade for information regarding the
subscription rights exercised by primary insiders in the Rights Issue and
Private Placement.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

– IMPORTANT INFORMATION –
This announcement is not and does not constitute an offer of securities for
sale or a solicitation of an offer to purchase securities of the Company in
the United States or any other jurisdiction. Copies of this document may not
be sent to jurisdictions, or distributed in or sent from jurisdictions, in
which this is barred or prohibited by law. The securities of the Company may
not be offered or sold in the United States absent registration or an
exemption from registration under the U.S. Securities Act of 1933, as amended
(the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act.
No public offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made
by means of a prospectus (the “Prospectus”) which will be prepared and which
is subject to the approval by the Norwegian Financial Supervisory Authority.
This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus will, following publication, be
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Managers.

In any EEA Member State other than Norway, this communication is only
addressed to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Regulation, i.e., only to investors who
can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of, the
Company. Neither the Manager nor any of its affiliates makes any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

Kilde

[Baerntis]

Dette innlegget ble rapportert og er midlertidig skjult.

[tverilytt]

Er det Entos de samarbeider med rundt dette? Eller andre?

[RakaBlakk]

Entos tester circVec med egen leveringsteknologi (PLV) og ikke AAV.

Så om man skal spekulere tester Circio dette med en undisclosed AAV-partner (det er jo tidligere nevnt at man har noen konfidensielle partnere).

EDW sa også tidligere i 2026 at de forventer like bra data i øye som med hjerte med 3.x og 4.0. De vet jo hvordan dette presterer løpende under testingen, så uttalelsen er vel basert på hva de observerer i lab’en as we speak.

[tverilytt]

Takk for forklaring og avklaring!

Ser det er selskap som kjører fase 1/2 studie for retina øyesykdom, de bruker AAV (sin egen proprietære plattform) som jeg skjønner det. Og cDNA? Er cDNA noe Circio kan bruke? Finner ikke flere detaljer. Ble nyskjerrig på om det kunne være noe Circio kan / kunne vært involvert i, kanskje indirekte.

[Baerntis]

Både Abbvie/Regenxbio og Adverum forventer data fra wet ADM fase 3 studier i 2026 og 2027, og har også pågående fase 1/2 studier. Det samme gjelder MeiraGTx (samt noen mindre biotechs) som gjorde en stor avtale med Eli Lilly for ikke lenge siden.

[Baerntis]

An Overview of In Vivo CAR-T Cell Therapy

Looking ahead, in vivo CAR-T technologies currently entering clinical development are expected to achieve increasingly precise spatial and temporal control of transgene expression while accommodating multiple synergistic mechanisms of action. As a result, these platforms may surpass the capabilities of existing therapeutic modalities and deliver superior clinical benefit across a broader spectrum of diseases. The conceptual shift from ex vivo to in vivo CAR-T cell therapy fundamentally redefines the scalability and accessibility of immunotherapy, with the potential to dramatically reduce manufacturing costs, generate profound socioeconomic impact, and accelerate the global dissemination of life-saving treatments.

[Baerntis]

@tverilytt

Og cDNA? Er cDNA noe Circio kan bruke?

Det er vel netopp det circvec erstater med sitt circvec-DNA og sirkulært RNA i motsetning til tradisjonell AAV-genterapi - lineær cDNA og lineær mRNA.

[HBA]

Fikk bare ca 30% av det jeg hadde overtegnet.
ASK konto

[Baerntis]

Siden AI-gestapo-folket har vært på ferde.

Siden 1H-2025 i august 2025, så har selskapet lagt frem/presentert circvec-data i

• Poster ESGCT oktober 2025

• Webcast 24. november

• Q4-2025

• Webcast 16. januar 2026

I tillegg så har EDW deltatt i intervju og lagt frem presentasjoner som ennå ikke er tilgjengelige på selskapets hjemmeside.

Gjennomgående i disse presentasjonene er at det ikke presenteres nye øyedata fra circvec-konstrukt etter v.2x (1H-2025), mens data fra hjerte som er selskapets andre inhouse fokus viser “progresjon” i v.3.2 og ytterligere boost i v.4x, og nå åpenbart har IND-enabling som retning/mål i 2026. Det samme gjelder (altså ingen oppdatering av) data for CNS som vi etterhvert har fått vite er i AAV-circvec brain/CNS-sporet, og da må være underlagt NDA i en god stund fremover (2H-2026).

Selv om EDW underveis og muntlig har lagt lista høyt også for nye øyedata, blir det ikke likevel litt merkelig at det ikke er presentert/presenteres nye data (f.eks fra v3.2) på samme måte som for hjerte ?

Kan vi da anta ett av følgende:

• At øye befinner seg i pågående AAV-feasibility / BD-spor ?
• At øye er bundet opp mot en spesifikk indikasjon - internt eller eksternt ?
• At øye for øyeblikket er nedprioritert, men at data fra v.2x brukes som dokumentasjon på at AAV-circVec fungerer in vivo

Ingen faste holdepunkt her. Kun et forsøk på å lese mellom linjene, eller å knytte sammen noen løse tråder. Det ble meldt 2 ukjente BDs i august 2025 (og nye samarbeid kan være ongoing). Siden et av disse BD-sporene med stor sannsynlighet er AAV-circvec, CNS er i feasibility/NDA, og hjerte skyves frem som inhouse fokus numero uno, hva så med øye ?

Meldes det snart avtale AAV-circvec/øye, eller har jeg lest kaffegruten feil ?

[tverilytt]

@Baerntis

Det er vel netopp det circvec erstater med sitt circvec-DNA

Ok ja, da er nok ikke Circio involvert i studiet jeg nevnte. Det er også klinisk og i gang, startet Q425, så uansett litt for tidlig ifht Circio?